Patents by Inventor Ling Ding
Ling Ding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130186546Abstract: A multi-layer material suitable for use as a covering for an article includes a polymeric cellular layer and nonwoven backing layer. The multi-layer material having a creasability angle of between about 20 and about 160 degrees.Type: ApplicationFiled: January 23, 2013Publication date: July 25, 2013Inventors: JIAN LING DING, ARTHUR VICTOR FLEURY, JR., CHARLES E. SNYDER, JASON CURTIS HINKLE, DANIEL T. BUNKER
-
Publication number: 20120186433Abstract: A ballistics shield material comprises an armor structure formed from armor material components. The armor structure is substantially imperforable by armor-piercing fire. The armor structure comprises at least multiple layers of high tensile material layers of para-aramid fabric, and an adhesive material for bonding components together. There is a visco elastic foam bonded with the adhesive. The foam can be acrylic foam is bonded with nitrile phenolic adhesive.Type: ApplicationFiled: March 29, 2010Publication date: July 26, 2012Applicant: SCAPA NORTH AMERICAInventors: Robert Joseph BRAIEWA, Jian Ling Ding, Davitt Cunningham, Kyle Robert Parent, Rengan Kannabiran
-
Patent number: 7763704Abstract: Endotoxin, also known as lipopolysaccharides (LPS), is the major mediator of septic shock due to Gram-negative bacterial infection. Chemically synthesized S3 peptide, derived from Sushi3 domain of Factor C, which is the endotoxin-sensitive serine protease of the limulus coagulation cascade, binds and neutralizes LPS activity. Fluorescent tagged-S3 is shown to detect LPS-containing bacteria. For large-scale production of S3 and to mimic other pathogen-recognizing molecules, tandem multimers of the S3 gene were constructed and expressed in E. coli. Tetramer of S3 for example is shown to display an enhanced inhibitory effect on LPS-induced activities. An affinity matrix based on tetramer of S3 is also shown to be particularly efficient at removing LPS.Type: GrantFiled: July 2, 2004Date of Patent: July 27, 2010Assignee: National University of SingaporeInventors: Jeak Ling Ding, Bow Ho
-
Publication number: 20100098846Abstract: A method is disclosed for making a soft adhesive tape. The method comprises providing a soft adhesive, rolling a gravure cylinder on the soft adhesive to meter the soft adhesive, depositing the metered soft adhesive from the gravure cylinder onto a carrier web, and transferring the soft adhesive to a backing substrate. In exemplary implementations, the method includes drying or curing the metered soft adhesive on the carrier web before transferring the soft adhesive to the backing substrate. A system is disclosed for making a layer of soft adhesive. The system comprises an applicator containing a soft adhesive, a gravure cylinder to meter the soft adhesive from the applicator, and a carrier web passing through the gravure cylinder, the carrier web supporting the metered soft adhesive deposited by the gravure cylinder. In exemplary implementations, a dryer may be included for curing the metered soft adhesive on the carrier web.Type: ApplicationFiled: September 28, 2009Publication date: April 22, 2010Applicant: SCAPA NORTH AMERICAInventors: Jian Ling Ding, Rengan Kannabiran, Kathryn Moon, Robert Braiewa, Brian Thomas
-
Publication number: 20080113906Abstract: Endotoxin, also known as lipopolysaccharides (LPS), is the major mediator of septic shock due to Gram-negative bacterial infection. Chemically synthesized S3 peptide, derived from Sushi3 domain of Factor C, which is the endotoxin-sensitive serine protease of the limulus coagulation cascade, binds and neutralizes LPS activity. Fluorescent tagged-S3 is shown to detect LPS-containing bacteria. For large-scale production of S3 and to mimic other pathogen-recognizing molecules, tandem multimers of the S3 gene were constructed and expressed in E. coli. Tetramer of S3 for example is shown to display an enhanced inhibitory effect on LPS-induced activities. An affinity matrix based on tetramer of S3 is also shown to be particularly efficient at removing LPS.Type: ApplicationFiled: July 2, 2004Publication date: May 15, 2008Inventors: Jeak Ling Ding, Bow Ho
-
Patent number: 7368023Abstract: Zirconium-rich bulk metallic glass alloys include quinary alloys containing zirconium, aluminum, titanium, copper and nickel. The bulk metallic glass alloys may be provided as completely amorphous pieces having cross-sectional diameters of at least about 5 mm or even greater.Type: GrantFiled: October 12, 2004Date of Patent: May 6, 2008Assignee: Wisconisn Alumni Research FoundationInventors: Y. Austin Chang, Hongbo Cao, Dong Ma, Ling Ding, Ker-chang Hsieh
-
Publication number: 20060153233Abstract: A wireless communication system (20) includes a wireless network (22) that communicates with a plurality of base stations (24) over a backhaul network (26). A disclosed example includes monitoring an amount of control traffic on the backhaul network (26) and dynamically and automatically adjusting an allocation of the backhaul resource for handling the control traffic. A disclosed example automatically allocates a remaining amount of the backhaul resource for handling bearer traffic.Type: ApplicationFiled: January 13, 2005Publication date: July 13, 2006Inventors: Ina Chen, Ling Ding, Mark Kraml, Harvey Rubin, Yang Yang
-
Publication number: 20060076089Abstract: Zirconium-rich bulk metallic glass alloys include quinary alloys containing zirconium, aluminum, titanium, copper and nickel. The bulk metallic glass alloys may be provided as completely amorphous pieces having cross-sectional diameters of at least about 5 mm or even greater.Type: ApplicationFiled: October 12, 2004Publication date: April 13, 2006Inventors: Y. Chang, Hongbo Cao, Dong Ma, Ling Ding, Ker-chang Hsieh
-
Patent number: 6923982Abstract: A calendered hydrocolloid dressing for the wound care and a one step method of manufacturing the hydrocolloidal dressing are described. In particular, the invention is concerned with a hydrocolloid dressing which is absorbent, non-damaging to the skin and comfortable to the user preferably having at least a thermoplastic elastomer backing and water absorbent polymeric adhesive layer.Type: GrantFiled: August 8, 2001Date of Patent: August 2, 2005Assignee: Scapa North AmericaInventors: Scott C. Barnes, Jim Jian Ling Ding
-
Patent number: 6841234Abstract: Heat-activated adhesive tape has a backing comprising 88-92% acrylic polymer containing: 35-45% of a first alkyl acrylate monomer with alkyl groups containing 4 to 12 carbon atoms, 30-40% of a second alkyl acrylate monomer with alkyl groups containing 4 to 12 carbon atoms, 6-10% a first monoethylenically unsaturated polar copolymerizable monomer, 1-2% a second monoethylenically unsaturated polar copolymerizable monomer, 0.3-0.5% photoinitiator, 1-2% filler, 0.05-0.07% crosslinker/chain extender, and 8-12% hollow glass microspheres; and heat-activated adhesive layer on at least one side. A pressure-sensitive adhesive may be on the other side.Type: GrantFiled: August 1, 2001Date of Patent: January 11, 2005Assignee: Scapa Tapes North America Inc.Inventors: Ramesh Lhila, Kwang-Yol Park, Kaila Delpozzo, Jian Ling Ding
-
Patent number: 6733997Abstract: A universal secretory signal originally derived from a piscine vitellogenin (Vtg) gene is inserted into various expression vectors for driving the secretion of the recombinant protein into the culture medium. This enhances the detection, quantification and downstream scaled-up purification of a recombinant protein of interest. The secretory signal system is very versatile, being conveniently and widely applicable to an array of heterologous host cells such as bacteria, yeast, insect, piscine, and mammalian cell lines (e.g., COS, CHO, NIH/3T3). The said secretory system is also applicable as a reporter vector for secretion of reporter proteins/enzymes, thus, enabling the detection of the reporter proteins (e.g., CAT, GFP) in the culture medium.Type: GrantFiled: October 26, 1999Date of Patent: May 11, 2004Assignee: National University of SingaporeInventors: Jeak Ling Ding, Nguan Soon Tan, Bow Ho, Toong Jin Lam
-
Patent number: 6645724Abstract: The horseshoe crab, Carcinoscorpius rotundicauda Factor C cDNA (CrFC21) has been cloned into a shuttle baculoviral vector and another vector suitable for expression in insect cells. The recombinant baculoviral DNA was then transfected into the insect cells for expression of recombinant Factor C. Recombinant Factor C was found to be immunoreactive and is capable of binding both free and bound/immobilized lipid A. It is enzymatically active when triggered by LPS. The rFC is probably of the two-chain form, being cleaved into the heavy and light chains after activation by Gram negative bacterial endotoxin. As low as 0.01 pg (0.001 ng/ml) of LPS was detectable by the rFC, thus, indicating its potentials as a novel generation of “limulus amoebocyte lysate.Type: GrantFiled: April 7, 1999Date of Patent: November 11, 2003Assignee: National University of SingaporeInventors: Jeak Ling Ding, Bow Ho
-
Publication number: 20030125680Abstract: A hydrocolloid bandage for the wound care designed for improved pliability and decreased peripheral edge lift. In particular, the invention is concerned with a hydrocolloid bandage which is absorbent, non-damaging to the skin and comfortable to the user preferably having at least a hydrocolloid region covered by film and adhesive layers which contact the user's skin at the periphery of the bandage.Type: ApplicationFiled: December 31, 2002Publication date: July 3, 2003Inventor: Jian Ling Ding
-
Publication number: 20020147265Abstract: Hydrocolloid compositions are provided having improved advantages over previous hydrocolloid compositions. The novel hydrocolloid compositions herein disclosed are particularly useful in the manufacturing of dressings for application to the skin of a user for wound care, displaying improved integrity, absorption and adhesion. Methods of manufacturing the hydrocolloid compositions are also provided.Type: ApplicationFiled: January 17, 2002Publication date: October 10, 2002Applicant: Scapa North AmericaInventors: Jian Ling Ding, Ferdinando J. D'Amato
-
Publication number: 20020106400Abstract: A calendered hydrocolloid dressing for the wound care and a one step method of manufacturing the hydrocolloidal dressing are described. In particular, the invention is concerned with a hydrocolloid dressing which is absorbent, non-damaging to the skin and comfortable to the user preferably having at least a thermoplastic elastomer backing and water absorbent polymeric adhesive layer.Type: ApplicationFiled: August 8, 2001Publication date: August 8, 2002Inventors: Scott C. Barnes, Jing Ling Ding
-
Publication number: 20020028326Abstract: Heat-activated adhesive tape has a backing comprising 88-92% acrylic polymer containing: 35-45% of a first alkyl acrylate monomer with alkyl groups containing 4 to 12 carbon atoms, 30-40% of a second alkyl acrylate monomer with alkyl groups containing 4 to 12 carbon atoms, 6-10% a first monoethylenically unsaturated polar copolymerizable monomer, 1-2% a second monoethylenically unsaturated polar copolymerizable monomer, 0.3-0.5% photoinitiator, 1-2% filler, 0.05-0.07% crosslinker/chain extender, and 8-12% hollow glass microspheres; and heat-activated adhesive layer on at least one side. A pressure-sensitive adhesive may be on the other side.Type: ApplicationFiled: August 1, 2001Publication date: March 7, 2002Applicant: Scapa Tapes North America Inc.Inventors: Ramesh Lhila, Kwang-yol Park, Kaila Delpozzo, Jian Ling Ding
-
Patent number: 5985590Abstract: CrFC21 cDNA was cloned into two mammalian vectors: pCIneo and pCDNAI, both of which carry the strong CMV promoter for expression in mammalian cell lines. Various CrFC cDNA constructs transformed into P. pastoris and S. cerevisiae were expressed to yield full-length recombinant Factor C (rCrFC) protein of .about.130 kDa which is immunoreactive. The rCrFC is expressed in an intracellular, insoluble form. Intracellular localization of the nascent protein provides protection from premature digestion by proteases secreted by the host cell. Subsequent to its synthesis, rCrFC is solubilized and purified under pyrogen-free conditions. Using established protocols, the protein can be denatured and renatured to recover its biological functionality. By manipulation of the 5' end of CrFC26, truncated constructs containing this cDNA are expressed by S. cerevisiae to give immunoreactive rCrFC. The rCrFC produced from both CrFC21 and CrFC26 constructs, solubilized by Triton X-100 or SDS, is found to be immunoreactive.Type: GrantFiled: June 18, 1997Date of Patent: November 16, 1999Assignee: National University of SingaporeInventors: Jeak Ling Ding, Bow Ho
-
Patent number: 5858706Abstract: CrFC21 cDNA was cloned into two mammalian vectors: pCIneo and pCDNAI, both of which carry the strong CMV promoter for expression in mammalian cell lines. Various CrFC cDNA constructs transformed into P. pastoris and S. cerevisiae were expressed to yield full-length recombinant Factor C (rCrFC) protein of .about.130 kDa which is immunoreactive. The rCrFC is expressed in an intracellular, insoluble form. Intracellular localization of the nascent protein provides protection from premature digestion by proteases secreted by the host cell. Subsequent to its synthesis, rCrFC is solubilized and purified under pyrogen-free conditions. Using established protocols, the protein can be denatured and renatured to recover its biological functionality. By manipulation of the 5' end of CrFC26, truncated constructs containing this cDNA are expressed by S. cerevisiae to give immunoreactive rCrFC. The rCrFC produced from both CrFC21 and CrFC26 constructs, solubilized by Triton X-100 or SDS, is found to be immunoreactive.Type: GrantFiled: February 2, 1996Date of Patent: January 12, 1999Assignee: National University of SingaporeInventors: Jeak Ling Ding, Bow Ho
-
Patent number: 5716834Abstract: Full-length and deletion subclones of cDNAs for Factor C of Carcinoscorpius rotundicauda are provided. These cDNAs have been cloned into .lambda.gt 22 and pGEM 11Zf(+). Further manipulations of the 5' and 3' ends of these cDNAs have been carried out, and these cDNAs have been further subcloned into other expression vectors such as pGEMEX-1, pET 3b, and the yeast shuttle vectors YEpsec 1 and pEMBLyex 4, and pPIC 9 and pHIL D2. Also provided are host cells transformed with expression vectors containing DNA molecules encoding proteins having Factor C-like enzymatic activity, methods of producing such proteins, methods for purifying Factor C zymogens, and methods for protecting Factor C zymogens from autoactivation by Gram negative bacterial endotoxin while the proenzyme is being purified and/or processed from amoebocyte lysates or from recombinant clones, or during storage or subsequent handling. This protection is afforded by the addition of 5-30% Me.sub.2 SO, which reversibly inhibits the Factor C zymogen.Type: GrantFiled: August 19, 1994Date of Patent: February 10, 1998Assignee: National University of SingaporeInventors: Jeak Ling Ding, Bow Ho
-
Patent number: 5712144Abstract: Full-length and deletion subclones of cDNAs for Factor C of Carcinoscorpius rotundicauda are provided. These cDNAs have been cloned into .lambda.gt 22 and pGEM 11Zf(+). Further manipulations of the 5' and 3' ends of these cDNAs have been carried out, and these cDNAs have been further subcloned into other expression vectors such as pGEMEX-1, pET 3b, and the yeast shuttle vectors YEpsec 1 and pEMBLyex 4, and pPIC 9 and pHIL D2. Also provided are host cells transformed with expression vectors containing DNA molecules encoding proteins having Factor C-like enzymatic activity, methods of producing such proteins, methods for purifying Factor C zymogens, and methods for protecting Factor C zymogens from autoactivation by Gram negative bacterial endotoxin while the proenzyme is being purified and/or processed from amoebocyte lysates or from recombinant clones, or during storage or subsequent handling. This protection is afforded by the addition of 5-30% Me.sub.2 SO, which reversibly inhibits the Factor C zymogen.Type: GrantFiled: June 2, 1995Date of Patent: January 27, 1998Assignee: National University of SingaporeInventors: Jeak Ling Ding, Bow Ho